Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
50 participants
INTERVENTIONAL
2019-04-01
2019-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of CFS and Fibromyalgia With HRG 80 Red Ginseng
NCT04599348
Effects of Ashwagandha Extract on Stress Levels
NCT06793891
A Study With Arctic Root Compared With the Extract When Combined With Schizandra and Russian Root (Adapt 232), Standardized Ginseng Extract and Placebo Regarding Impact on the Level of Energy, Ability to Work Under Stress, Quality of Life and Wellbeing, in Middleaged Women Who Are Still Employed
NCT01006460
A Study on the Effects of VR-3 Herbal Blend Intake on Acute and Chronic Stress in Healthy Adults
NCT00741962
Acute Effects of a Botanical Extract and Its Main Volatile Compound on Stress Response in Healthy Adults
NCT04523870
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HRG80 Panax ginseng
Panax ginseng standardized to 63.4 mg of total ginsenosides taken orally once daily in the morning after a meal.
HRG80 Panax ginseng
Panax ginseng containing 63.4 mg ginsenosides
Panax ginseng
Panax ginseng standardized to 19.6 mg of total ginsenosides taken orally once daily in the morning after a meal.
Panax ginseng
Panax ginseng containing 19.6 mg ginsenosides
Placebo
Placebo capsule containing brown sugar and rice flour, taken orally once daily in the morning after a meal.
Placebo
800 mg excipient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HRG80 Panax ginseng
Panax ginseng containing 63.4 mg ginsenosides
Panax ginseng
Panax ginseng containing 19.6 mg ginsenosides
Placebo
800 mg excipient
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women ages 18-65 (all races and ethnicities)
* Able to understand and participate in an 11-week study
Exclusion Criteria
* Consuming more than 1 cup of coffee daily (in the morning).
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Botalys SA
UNKNOWN
EuroPharma, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Areg Hovhannisyan, PhD, Dr Sci
Role: PRINCIPAL_INVESTIGATOR
Sports Medicine and Anti-Doping Service Republican Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sports Medicine and Anti-Doping Service Republican Centre
Yerevan, , Armenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EP-1005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.